Skip to content
Homepage
Author:
Wuxi Biologics
Posted Date:
July 9, 2026
WuXi Biologics’ MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy
Wuxi Biologics
July 9, 2026
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year
Wuxi Biologics
July 8, 2026
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy
Wuxi Biologics
June 30, 2026
WuXi Biologics’ 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations
Wuxi Biologics
June 24, 2026
WuXi Biologics’ Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
Wuxi Biologics
June 18, 2026
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards
Wuxi Biologics
June 8, 2026
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
Wuxi Biologics
June 4, 2026
WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year
Wuxi Biologics
June 2, 2026
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
Wuxi Biologics
May 27, 2026
WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index
Wuxi Biologics
May 12, 2026
1
2
3
Next
